Tags

Type your tag names separated by a space and hit enter

Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy.

Abstract

In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and A H3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-gamma levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0 +/- 229.8 pg/ml to a 30-day level of 390.7 +/- 606.3 pg/ml (P < 0.05), with concentrations significantly higher (P < 0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4+ cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy.

    , , , , , , ,

    Source

    Journal of medical virology 78:4 2006 Apr pg 440-5

    MeSH

    Adolescent
    Antibodies, Viral
    Antiretroviral Therapy, Highly Active
    Child
    Female
    HIV Infections
    HIV-1
    Humans
    Influenza A Virus, H1N1 Subtype
    Influenza A Virus, H3N2 Subtype
    Influenza B virus
    Influenza Vaccines
    Influenza, Human
    Interferon-gamma
    Lymphocyte Activation
    Male
    T-Lymphocytes
    Treatment Outcome
    Viral Load
    Virosomes
    Virus Replication

    Pub Type(s)

    Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    16482542

    Citation

    Tanzi, Elisabetta, et al. "Immunogenicity and Effect of a Virosomal Influenza Vaccine On Viral Replication and T-cell Activation in HIV-infected Children Receiving Highly Active Antiretroviral Therapy." Journal of Medical Virology, vol. 78, no. 4, 2006, pp. 440-5.
    Tanzi E, Esposito S, Bojanin J, et al. Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. J Med Virol. 2006;78(4):440-5.
    Tanzi, E., Esposito, S., Bojanin, J., Amendola, A., Trabattoni, D., Pariani, E., ... Principi, N. (2006). Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. Journal of Medical Virology, 78(4), pp. 440-5.
    Tanzi E, et al. Immunogenicity and Effect of a Virosomal Influenza Vaccine On Viral Replication and T-cell Activation in HIV-infected Children Receiving Highly Active Antiretroviral Therapy. J Med Virol. 2006;78(4):440-5. PubMed PMID: 16482542.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. AU - Tanzi,Elisabetta, AU - Esposito,Susanna, AU - Bojanin,Jelena, AU - Amendola,Antonella, AU - Trabattoni,Daria, AU - Pariani,Elena, AU - Pinzani,Raffaella, AU - Zanetti,Alessandro, AU - Principi,Nicola, PY - 2006/2/17/pubmed PY - 2006/5/27/medline PY - 2006/2/17/entrez SP - 440 EP - 5 JF - Journal of medical virology JO - J. Med. Virol. VL - 78 IS - 4 N2 - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and A H3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-gamma levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0 +/- 229.8 pg/ml to a 30-day level of 390.7 +/- 606.3 pg/ml (P < 0.05), with concentrations significantly higher (P < 0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4+ cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients. SN - 0146-6615 UR - https://www.unboundmedicine.com/medline/citation/16482542/Immunogenicity_and_effect_of_a_virosomal_influenza_vaccine_on_viral_replication_and_T_cell_activation_in_HIV_infected_children_receiving_highly_active_antiretroviral_therapy_ L2 - https://doi.org/10.1002/jmv.20559 DB - PRIME DP - Unbound Medicine ER -